174 related articles for article (PubMed ID: 25687379)
21. Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors.
Omae K; Fukuma S; Ikenoue T; Kondo T; Takagi T; Ishihara H; Tanabe K; Fukuhara S
Urol Oncol; 2017 Sep; 35(9):540.e7-540.e12. PubMed ID: 28624136
[TBL] [Abstract][Full Text] [Related]
22. High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma.
Pan D; Xu L; Liu H; Zhang W; Liu W; Liu Y; Fu Q; Xu J
Cancer Sci; 2015 May; 106(5):592-7. PubMed ID: 25702890
[TBL] [Abstract][Full Text] [Related]
23. Multi-institutional analysis of localized renal cell carcinoma that demonstrates the impact of diabetic status on prognosis after nephrectomy.
Ha YS; Kim WT; Yun SJ; Lee SC; Kim WJ; Park YH; Kang SH; Hong SH; Byun SS; Kim YJ
Ann Surg Oncol; 2013 Oct; 20(11):3662-8. PubMed ID: 23907313
[TBL] [Abstract][Full Text] [Related]
24. Increased preoperative levels of plasma fibrinogen and D dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics.
Erdem S; Amasyali AS; Aytac O; Onem K; Issever H; Sanli O
Urol Oncol; 2014 Oct; 32(7):1031-40. PubMed ID: 25027687
[TBL] [Abstract][Full Text] [Related]
25. Renal fossa recurrence after nephrectomy for renal cell carcinoma: prognostic features and oncological outcomes.
Psutka SP; Heidenreich M; Boorjian SA; Bailey GC; Cheville JC; Stewart-Merrill SB; Lohse CM; Atwell TD; Costello BA; Leibovich BC; Thompson RH
BJU Int; 2017 Jan; 119(1):116-127. PubMed ID: 27489013
[TBL] [Abstract][Full Text] [Related]
26. Preoperative Anemia as an Independent Prognostic Indicator of Papillary Renal Cell Carcinoma.
Huang J; Feldman AS; Dong L; Cornejo K; Liu Q; Dahl DM; Wu S; Blute ML; Huang Y; Wu CL
Clin Genitourin Cancer; 2015 Oct; 13(5):e353-60. PubMed ID: 25998556
[TBL] [Abstract][Full Text] [Related]
27. Prognostic role of tumour multifocality in renal cell carcinoma.
Siracusano S; Novara G; Antonelli A; Artibani W; Bertini R; Carini M; Carmignani G; Ciciliato S; Cunico SC; Lampropoulou N; Longo N; Martorana G; Minervini A; Mirone V; Simeone C; Simonato A; Valotto C; Zattoni F; Ficarra V;
BJU Int; 2012 Dec; 110(11 Pt B):E443-8. PubMed ID: 22502873
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors in a large multi-institutional series of papillary renal cell carcinoma.
Zucchi A; Novara G; Costantini E; Antonelli A; Carini M; Carmignani G; Cosciani Cunico S; Fontana D; Longo N; Martignoni G; Minervini A; Mirone V; Porena M; Roscigno M; Schiavina R; Simeone C; Simonato A; Siracusano S; Terrone C; Ficarra V
BJU Int; 2012 Apr; 109(8):1140-6. PubMed ID: 21871053
[TBL] [Abstract][Full Text] [Related]
29. The prognostic value of erythrocyte polyamines in the preoperative evaluation of patients with renal cell carcinoma.
Lughezzani G; Karakiewicz PI; Bigot P; Perrotte P; Crépel M; Rioux-Leclercq N; Catros-Quemener V; Moulinoux JP; Bouet F; Cipolla B; Patard JJ
Eur J Cancer; 2010 Jul; 46(10):1927-35. PubMed ID: 20335019
[TBL] [Abstract][Full Text] [Related]
30. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma.
Kaffenberger SD; Lin-Tsai O; Stratton KL; Morgan TM; Barocas DA; Chang SS; Cookson MS; Herrell SD; Smith JA; Clark PE
Urol Oncol; 2015 Jan; 33(1):21.e11-21.e17. PubMed ID: 25456998
[TBL] [Abstract][Full Text] [Related]
31. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma.
Sengupta S; Lohse CM; Cheville JC; Leibovich BC; Thompson RH; Webster WS; Frank I; Zincke H; Blute ML; Kwon ED
Cancer; 2006 Jan; 106(2):304-12. PubMed ID: 16353202
[TBL] [Abstract][Full Text] [Related]
32. Oncological outcomes of patients with incidental pathological T3a stage small renal cell carcinoma after partial nephrectomy.
Lee C; You D; Yoo S; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2016 Jul; 142(7):1651-7. PubMed ID: 27193144
[TBL] [Abstract][Full Text] [Related]
33. Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma--results from a comprehensive multi-centre database (CORONA/SATURN-Project).
Brookman-May SD; May M; Shariat SF; Novara G; Zigeuner R; Cindolo L; De Cobelli O; De Nunzio C; Pahernik S; Wirth MP; Longo N; Simonato A; Serni S; Siracusano S; Volpe A; Morgia G; Bertini R; Dalpiaz O; Stief C; Ficarra V; ; ;
BJU Int; 2013 Nov; 112(7):909-16. PubMed ID: 23890378
[TBL] [Abstract][Full Text] [Related]
34. The impact of perioperative blood transfusion on survival after nephrectomy for non-metastatic renal cell carcinoma (RCC).
Linder BJ; Thompson RH; Leibovich BC; Cheville JC; Lohse CM; Gastineau DA; Boorjian SA
BJU Int; 2014 Sep; 114(3):368-74. PubMed ID: 24471825
[TBL] [Abstract][Full Text] [Related]
35. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study.
Lee H; Lee SE; Byun SS; Kim HH; Kwak C; Hong SK
BJU Int; 2017 Feb; 119(2):261-267. PubMed ID: 27226065
[TBL] [Abstract][Full Text] [Related]
36. Clinical and oncological outcomes in Chinese patients with renal cell carcinoma and venous tumor thrombus extension: single-center experience.
Chen X; Li S; Xu Z; Wang K; Fu D; Liu Q; Wang X; Wu B
World J Surg Oncol; 2015 Feb; 13():14. PubMed ID: 25650039
[TBL] [Abstract][Full Text] [Related]
37. Mean platelet volume-to-lymphocyte ratio: a novel biomarker associated with overall survival in patients with nonmetastatic clear cell renal cell carcinoma treated with nephrectomy.
Życzkowski M; Kaletka Z; Rajwa P; Rempega G; Stelmach P; Bogacki R; Łach-Wojnarowicz O; Paradysz E
Int Urol Nephrol; 2020 May; 52(5):885-891. PubMed ID: 31953718
[TBL] [Abstract][Full Text] [Related]
38. Impact of macroscopic tumour necrosis to predict survival of patients with surgically resected renal cell carcinoma.
Pflanz S; Brookman-Amissah S; Roigas J; Kendel F; Hoschke B; May M
Scand J Urol Nephrol; 2008; 42(6):507-13. PubMed ID: 19031267
[TBL] [Abstract][Full Text] [Related]
39. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
40. Histologic subtype impacts cancer-specific survival in patients with sarcomatoid-variant renal cell carcinoma treated surgically.
Nguyen DP; Vilaseca A; Vertosick EA; Corradi RB; Touijer KA; Benfante NE; Sjoberg DD; Russo P
World J Urol; 2016 Apr; 34(4):539-44. PubMed ID: 26215750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
